Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTOPIA: Tenecteplase for Acute Ischemic Stroke With Unknown Time of Onset
NCT07475949Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Excellent outcome (modified Rankin Scale score 0-1) at 90 days. Started Sep 2026; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07475949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475949.